Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) – A subgroup analysis of the ARIES-E clinical trial

Respiratory Medicine

Volumn 117, Issue , 2016, Pages 254-263

  Fischer, Aryeh ^a   Denton, Christopher P ^b   Matucci Cerinic, Marco ^c   Gillies, Hunter ^d   Blair, Christiana ^d   Tislow, James ^d   Nathan, Steven D ^e  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF FLORENCE   (Italy)

^d GILEAD SCIENCES   (United States)

^e INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Ambrisentan; Connective tissue diseases; Outcome assessment; Pulmonary hypertension

Indexed keywords

AMBRISENTAN; PROSTANOID; SILDENAFIL; VARDENAFIL; ANTIHYPERTENSIVE AGENT; ENDOTHELIN A RECEPTOR ANTAGONIST; PHENYLPROPIONIC ACID DERIVATIVE; PYRIDAZINE DERIVATIVE;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL (TOPIC); CONNECTIVE TISSUE DISEASE; COUGHING; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HEART RIGHT VENTRICLE FAILURE; HUMAN; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RHINOPHARYNGITIS; SURVIVAL ANALYSIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WALKING; AGED; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PREVALENCE; PROCEDURES; TREATMENT OUTCOME; WALK TEST;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CONNECTIVE TISSUE DISEASES; DOUBLE-BLIND METHOD; ENDOTHELIN A RECEPTOR ANTAGONISTS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHENYLPROPIONATES; PREDICTIVE VALUE OF TESTS; PREVALENCE; PYRIDAZINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WALK TEST;

EID: 84978087054     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2016.06.018     Document Type: Article

References (27)

1. [1] Yang, X., Mardekian, J., Sanders, K.N., Mychaskiw, M.A., Thomas, J. 3rd, Prevalence of pulmonary arterial hypertension in patients with connective tissue disease: a systematic review of the literature. Clin. Rheumatol. 32 (2013), 1519–1531.
2. [2] Condliffe, R., Kiely, D.G., Peaock, A.J., Corris, P.A., Gibbs, J.S., Vrapi, F., et al. Connective tissue disease – associated pulmonary arterial hypertension in the modern treatment era. Am. J. Respir. Crit. Care Med. 179 (2009), 151–157.
3. [3] Chung, L., Liu, J., Parsons, L., Hassoun, P.M., McGoon, M., Badesch, D.B., et al. Characterization of connective tissue disease – associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 138 (2010), 1383–1394.
4. [4] Humbert, M., Yaici, A., de Groote, P., Montani, D., Sitbon, O., Launay, D., et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum. 63 (2011), 3522–3530.
5. [5] Ruiz-Cano, M.J., Escribano, P., Alonso, R., Delgado, J., Carreira, P., Velazquez, T., et al. Comparison of baseline characteristics and survival between patients with idiopathic and connective tissue disease-related pulmonary arterial hypertension. J. Heart Lung Transpl. 28 (2009), 621–627.
6. [6] Hurdman, J., Condliffe, R., Elliot, C.A., Davies, C., Hill, C., Wild, J.M., et al. Aspire registry: assessing the spectrum of pulmonary hypertension identified at a referral center. Eur. Respir. J. 39 (2012), 945–955.
7. [7] Lynch, J.P. 3rd, Balperio, J.A., Saggar, R., Fishbein, M.C., Saggar, R., Pulmonary hypertension complicating connective tissue disease. Semin. Respir. Crit. Care Med. 34 (2013), 581–599.
8. [8] Pamidi, S., Mehta, S., Six-minute walk test in scleroderma – associated pulmonary arterial hypertension: are we counting what counts?. J. Rheumatol. 36 (2009), 216–218.
9. [9] Minai, O.A., Blair, C., Heresi, G.A., Gillies, H., Change in 6MWD as a predictor of survival in PAH: minimal clinically important difference (MID) and beyond [abstract]. Am. J. Respir. Crit. Care Med., 189, 2014, A4767.
10. [10] Galiè, N., Torbicki, A., Barst, R., Dartevelle, P., Haworth, S., Higgenbottam, J., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur. Heart J. 25 (2004), 2243–2278.
11. [11] Badesch, D.B., Abman, S.H., Ahearn, G.S., Barst, R.J., McCrory, D.C., Simonneau, G., et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (2004), 35S–62S.
12. [12] Galiè, N., Olschewski, H., Oudiz, R.J., Torres, F., Frost, A., Ghofrani, H.A., et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension randomized, double-blind, placebo-controlled, multicenter efficacy (ARIES) study 1 and 2. Circulation 117 (2008), 3010–3019.
13. [13] Oudiz, R.J., Galiè, N., Olschewski, H., Torres, F., Frost, A., Ghofrani, H.A., et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54 (2009), 1971–1981.
14. [14] Mathai, S.C., Puhan, M.A., Lam, D., Wise, R.A., The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 186 (2012), 428–433.
15. [15] Gabler, N.B., French, B., Strom, B.L., Palevsky, H.I., Taichman, D.B., Kawut, S.M., et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 126 (2012), 349–356.
16. [16] Badesch, D.B., Tapson, V.F., McGoon, M.D., Brundage, B.H., Rubin, L.J., Wigley, F.M., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann. Intern Med. 132 (2000), 425–434.
17. [17] Denton, C.P., Humbert, M., Rubin, L., Black, C.M., Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann. Rheum. Dis. 65 (2006), 1336–1340.
18. [18] Girgis, R.E., Frost, A.E., Hill, N.S., Horn, E.M., Langleben, D., McLaughlin, V.V., et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann. Rheum. Dis. 66 (2007), 1467–1472.
19. [19] Denton, C.P., Pope, J.E., Peter, H.H., Gabrielli, A., Boonstra, A., van den Hoogen, F.H., et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann. Rheum. Dis. 67 (2008), 1222–1228.
20. [20] Badesch, D.B., Hill, N.S., Burgess, G., Rubin, L.J., Barst, R.J., Galiè, N., et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J. Rheumatol. 34 (2007), 2417–2422.
21. [21] Avouac, J., Wipff, J., Kahan, A., Allanore, Y., Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomized controlled trials. Ann. Rheum. Dis. 67 (2008), 808–814.
22. [22] Lederer, D.J., Arcasoy, S.M., Wilt, J.S., D'Ovidio, F., Sonett, J.R., Kawut, S.M., Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 174 (2006), 659–664.
23. [23] Miyamoto, S., Nagaya, N., Satoh, T., Kyotani, S., Sakamaki, F., Fujita, M., et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am. J. Respir. Crit. Care Med. 161 (2000), 487–492.
24. [24] Garin, M.C., Highland, K.B., Silver, R.M., Strange, C., Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J. Rheumatol. 36 (2009), 330–336.
25. [25] Launay, D., Sitbon, O., Hachulla, E., Mouthon, L., Gressin, V., Rottat, L., et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann. Rheum. Dis. 72 (2013), 1940–1946.
26. [26] Condliffe, R., Howard, L.S., Connective tissue disease-associated pulmonary arterial hypertension. F1000 Prime Rep., 7, 2015, 06.
27. [27] Benza, R.L., Miller, D.P., Gomberg-Maitland, M., Frantz, R.P., Foreman, A.J., Coffey, C.S., et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 122 (2010), 164–172.